GeoVax Initiates Research on Needle-Free GEO-MVA Vaccine Using Vaxxas HD-MAP Technology

GeoVax Labs, Inc., a clinical-stage biotechnology company, has announced the start of a research program to assess the immunogenicity and stability of its GEO-MVA vaccine when delivered through Vaxxas' high-density microarray patch (HD-MAP) platform. This preclinical study, conducted at the University of Queensland, aims to validate the potential of a thermostable, needle-free vaccine delivery system that could revolutionize immunization practices worldwide.

The study focuses on the immune responses, delivery efficiency, and thermostability of GEO-MVA formulated onto HD-MAPs for administration in mice. The HD-MAP technology offers a promising alternative to traditional needle-and-syringe methods, with benefits including self-administration, increased patient acceptance, higher immunogenicity, and reduced reliance on cold chain storage. These advantages could significantly impact pandemic response, biodefense stockpiling, and immunization programs in low- and middle-income countries.

David Dodd, Chairman and CEO of GeoVax, highlighted the program's potential to expand the versatility of the company's MVA platform, offering a more accessible and effective vaccine solution. The success of this study could lead to the development of a vaccine that not only eliminates the need for needles but also provides stronger immune responses at lower doses and greater stability under varying temperatures.

The Vaxxas HD-MAP platform has already shown enhanced immunogenicity in various studies, and partnerships with leading pharmaceutical and government entities are advancing its development. GeoVax's recent favorable scientific advice from the European Medicines Agency (EMA) further supports the streamlined regulatory pathway for GEO-MVA, potentially expediting its development and approval as an Mpox vaccine candidate in the EU.

This research represents a significant step forward in addressing global health challenges by improving vaccine accessibility and effectiveness. The implications of a successful needle-free, self-administered vaccine are vast, offering a solution that could transform immunization strategies and enhance global health security.